诊疗指南

2016 CCO实践指南:利妥昔单抗治疗淋巴瘤和慢性淋巴细胞白血病

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline
2017-01-20 15:38 发表评论

The systematic review process was developed by the CCO-PEBC. The PEBC is supported by the Ontario Ministry of Health and Long-term Care. All work produced by the PEBC is editorially independent from the Ministry. This evidentiary base is composed of three parts: the evidentiary base of Version 2, the results of the updated search executed in March 2012 and the content of a further update executed in October 2013. Each of the searches was developed using a planned two-stage method and this document reports the methods used for the most recent update; methods for previous versions are very similar and are available upon request. The working group of the Hematology DSG comprising physicians with content expertise, epidemiologists and consumers developed this evidentiary base upon which these guideline recommendations are based.

    
学科代码:肿瘤学   关键词:2016 CCO实践指南 利妥昔单抗 淋巴瘤 慢性淋巴细胞白血病 ,指南 爱思唯尔医学网, Elseviermed
顶一下(0
您可能感兴趣的指南
发表评论网友评论(0)
发表评论
登录后方可发表评论,点击此处登录